{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:19:00Z","timestamp":1793319540772,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009575","name":"Jacques und Gloria Gossweiler-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009575","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.rpth.2026.103405","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T17:03:03Z","timestamp":1772643783000},"page":"103405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Daratumumab for relapsed refractory immune thrombotic thrombocytopenic purpura: initial response and long-term follow-up"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0846-8508","authenticated-orcid":false,"given":"Roman","family":"Schimmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5371-3643","authenticated-orcid":false,"given":"Jana","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1914-4556","authenticated-orcid":false,"given":"Marissa","family":"Schraner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8687-9620","authenticated-orcid":false,"given":"Alice","family":"Trinchero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2394-2223","authenticated-orcid":false,"given":"Andreas","family":"Holbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1300-7135","authenticated-orcid":false,"given":"Johanna A.","family":"Kremer Hovinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4221-8596","authenticated-orcid":false,"given":"Jan-Dirk","family":"Studt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.103405_bib1","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.103405_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103168","article-title":"Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project)","volume":"82","author":"Coppo","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.rpth.2026.103405_bib3","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.103405_bib4","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103405_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103405_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"25","author":"Owattanapanich","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.103405_bib7","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.103405_bib8","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.103405_bib9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1600-0609.2007.00832.x","article-title":"Mycophenolate mofetil in a case of relapsed, refractory thrombotic thrombocytopenic purpura","volume":"78","author":"Ahmad","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.rpth.2026.103405_bib10","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1182\/bloodadvances.2022007632","article-title":"Efficacy and safety of azathioprine during remission of immune-mediated thrombotic thrombocytopenic purpura","volume":"6","author":"Bichard","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.103405_bib11","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","article-title":"Splenectomy and\/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"52","author":"Beloncle","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.rpth.2026.103405_bib12","doi-asserted-by":"crossref","first-page":"987","DOI":"10.7326\/0003-4819-118-12-199306150-00022","article-title":"Cyclosporine for thrombotic thrombocytopenic purpura","volume":"118","author":"Kierdorf","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rpth.2026.103405_bib13","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bjh.13993","article-title":"Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura","volume":"173","author":"Patriquin","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.103405_bib14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/bjh.18192","article-title":"The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura","volume":"198","author":"Doyle","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.103405_bib15","first-page":"320","article-title":"Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura","volume":"89","author":"Kremer Hovinga","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.103405_bib16","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2014-04-561142","article-title":"The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs","volume":"124","author":"Schaller","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.103405_bib17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mah\u00e9vas","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.rpth.2026.103405_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.tmrv.2021.06.002","article-title":"Daratumumab: beyond multiple myeloma","volume":"35","author":"Ejaz","year":"2021","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.rpth.2026.103405_bib19","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1182\/bloodadvances.2021005124","article-title":"Daratumumab for immune thrombotic thrombocytopenic purpura","volume":"6","author":"Van den Berg","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.103405_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjh.18854","article-title":"Daratumumab for refractory immune-mediated thrombotic thrombocytopenic purpura","volume":"202","author":"Aggarwal","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.103405_bib21","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1111\/bjh.19752","article-title":"Efficacy and safety of daratumumab in multiresistant immune-mediated thrombotic thrombocytopenic purpura","volume":"205","author":"Weisinger","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.103405_bib22","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.103405_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11239-023-02768-z","article-title":"Combination regimens containing daratumumab for initial diagnosed acquired thrombotic thrombocytopenic purpura","volume":"55","author":"Xie","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2026.103405_bib24","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/bloodadvances.2022007025","article-title":"Alterations in B- and circulating T-follicular helper cell subsets in immune thrombotic thrombocytopenic purpura","volume":"6","author":"Shin","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.103405_bib25","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.tmrv.2022.09.001","article-title":"Plasma cell directed therapy for immune thrombotic thrombocytopenic purpura (iTTP)","volume":"36","author":"Chen","year":"2022","journal-title":"Transfus Med Rev"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926000634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926000634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:03:05Z","timestamp":1779451385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926000634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2475037926000634"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103405","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daratumumab for relapsed refractory immune thrombotic thrombocytopenic purpura: initial response and long-term follow-up","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103405"}}